Categories
Uncategorized

Hypertrophic cardiomyopathy

Defined as myocardial hypertrophy in the absence of another cause.

Has significant genotypic, phenotypic and clinical heterogeneity.

Among the leading causes of identifiable sudden cardiac death in the young.

The most common inherited cardiac disease in the general population.

A common genetic disease with worldwide distribution, broad-spectrum clinical outcome.

Autosomal dominant process with hypertrophy of the left ventricle and sometimes the right, and often with predominate involvement of the intraventricular septum.

Affects men and women equally, and is present in persons of diverse  ethnic backgrounds.

The left ventricular outflow tract obstruction is present or develops over time in 70% of patients with hypertrophic cardio myopathy.

One of the major determinant of exercise intolerance and limiting symptoms among patients with HCM is an elevated intracardiac pressure that results from left ventricular outflow tract obstruction.

Hypertrophy or displacement of the papillary muscles, anomalous insertion of the papillary muscles, and elongation of the mitral valve leaflets with systolic anterior motion and posterior directed mitral regurgitation are common ECHO features.

It is characterized by a thickened, non-dilated left ventricle, and is associated with exertional dyspnea, reduced exercise capacity, all of which can impair the quality of life.

The left ventricular outflow tract obstruction results from contact of the mitral valve with the ventricular septumduring systole is the one of the principal determinants of HCM related complications.

Caused by mutations in suPAR o Eric proteins.

Cardiac hypercontractility results from excessive numbers of actin-myosin cross bridges within the cardiac sarcomere.

Additionally, elongation of the mitral valve leaflets, apical displacement of the papillary. muscles and protrusion of the hypertrophied ventricular septum into the left ventricular outflow tract promote outflow obstruction.

The impedance to blood flow generates a left ventricular outflow tract pressure gradient, which can be quantified by echocardiography.

HCM is often a genetic disease of autosomal dominant inheritance.

Associated with more than 1000 mutations in 11 genes.

Most variance in code components of the sarcomere.

Genetic tests are negative and approximately 50% of all unrelated patients with HCM.

Gene abnormalities encode components of the contractile apparatus of heart muscle and the genes encoding sarcomeric proteins cause hypertrophic cardiomyopathy.

Prevalence of 1 per 200-500 in the U.S. population and higher in blacks.

Can affect individuals of all ages.

Inheriteded primarily as an autosomal dominant, although sporadic mutations occur.

Significant proportion of cases occur in a familial pattern.

Mutations in any one of the genes involved are found in up to two thirds of patients with hypertrophic cardiomyopathy.

Familial hypertrophic cardiomyopathy inherited as an autosomal dominant pattern.

Doppler velocities of the mitral annulus correlate with global systolic and diastolic left ventricular performance and can predict prehypertrophy sarcomere dysfunction.

Hallmark features Includes myocyte fibrosis and disarray.

Myocardial fibrosis is a prominent pathophysiologic component of this complex genetic disease, related to the risk of sudden death and heart failure.

Many cases associated with a mutation in the genes that codes for the proteins of the cardiac sarcomere.

Mutations in MYH7, encoding the β -myosin heavy chain, and in MYBPC3, encoding cardiac myosin-biding protein Care the most common, with each accounting for one quarter to one third of all cases of the disease, and the remaining genes each account for less than 1-5% of cases (Richard P et al).

Beta-myosin heavy chain mutations provide the pathogenic basis of this disease with disease of the myofilament.

Myocyte dysfunction precedes hypertrophy.

Left ventricular replacement fibrosis and scarring has been implicated in triggering life-threatening arrhythmias, ventricular fibrillation and a marker for sudden death.

Heterogenous disorder associated with myofibril disarray and asymmetric myocardial hypertrophy of the ventricular septum or apex.

Mitral valve incompetence is almost invariably present with left ventricular outflow obstruction.

Congestive heart failure is 5 times more likely than in an unaffected population.

Most patients have left ventricular outlet tract obstruction (LVOT), which is typically due to systolic anterior motion of the mitral valve leaflets.

Most patients are asymptomatic.

LVOT obstruction may occur at rest or be latent being manifest, by activity.

Most common monogenic heart disorder and cause of death from cardiac causes in children and adolescents.

If pressure gradients of >30 mm Hg are present at rest, the potential for further hypertrophy and deterioration is highly likely.

Ventricular arrhythmias may precipitate sudden death.

Most common cause of sudden death in young people.

Symptoms can be caused by diastolic dysfunction, mitral regurgitation and myocardial ischemia.

Diagnostic suspicion related to symptoms, physical exam findings, family history, or LVH on EKG,

Symptoms include:dyspnea on exertion, dizziness, presyncope, syncope, anginal or non-anginal chest pains, and palpitations.

Clinical exam findings include sustained LV impulse, sytolic murmur, S4 sound, bifid carotid carotid upstroke and spike and dome arterial pulse.

EKG demonstrates giant negative T waves associated with high QRS voltage in the lateral precordial leads despite the absence of hypertension and coronary artery disease.

Coronary artery disease is present in up to 20% of patients with hypertrophic cardio myopathy and severe coronary disease is associated with disproportionately increased risk of death in hypertrophic cardiomyopathy.

Relationship between the depth of inverted T waves and the apex/midwall thickness ratio suggest that the abnormal repolarization of the hypertrophied apical musculature causes these giant T wave inversions.

Systolic murmur due to LVOT obstruction and or mitral regurgitation, usually at the left sternal border.

The murmur of obstructive hypertrophic cardiomyopathy increases with decreased preload or decreased after load and it decreases on the opposite conditions.

The murmur of obstructive hypertrophic cardiomyopathy increases with squat to stand and Valsalva maneuvers and decreases with stand to squat or handgrip maneuvers.

Late gadolinium enhancement may identify patients who can benefit from a primary prevention of sudden death with implantable cardioverter-defibrillators, or who evolve to the end stage of this disease with systolic dysfunction and consideration for heart transplant.

Invasive therapies for obstructive HCM include surgical myectomy and percutaneous alcohol septal ablation are effective in relieving left ventricular outflow tract gradients and favorably affect the clinical course and relief of symptoms.

Surgical mortality ranges from <2% to 5% for myectomy.

Nonsurgical myocardial reduction with dessicated alcohol infused into the first major septal perforator of the left anterior descending coronary artery associated with a hospital mortality between 0 and 4%.

In elderly patients diagnosed in the fifth or sixth decades of life have a morphological subtype of disease characterized as a sigmoid ventricular septum compared with patients diagnosed at a young age.

Older populations of patients have fewer symptoms and fewer sudden deaths.

Beta-myosin heavy chain mutations provide the pathogenic basis of this disease with disease of the myofilament.

Myocyte dysfunction precedes hypertrophy.

Heterogenous disorder associated with myofibril disarray and asymmetric myocardial hypertrophy of the ventricular septum or apex.

Mitral valve incompetence is almost invariably present with left ventricular outflow obstruction.

Congestive heart failure is 5 times more likely than in an unaffected population.

Most patients have left ventricular outlet tract obstruction (LVOT), which is typically due to systolic anterior motion of the mitral valve leaflets.

LVOT obstruction may occur at rest or be latent being manifest, by activity.

Most common monogenic heart disorder and cause of death from cardiac causes in children and adolescents.

If pressure gradients of >30 mm Hg are present at rest, the potential for further hypertrophy and deterioration is highly likely.

Ventricular arrhythmias may precipitate sudden death.

Most common cause of sudden death in young people.

Symptoms can be caused by diadtolic dysfunction, mitral regurgitation and myocardial ischemia.

Diagnostic suspicion related to symptoms, physical exam findings, family history, or LVH on EKG,

Symptoms include:dyspnea on exertion, dizziness, presyncope, syncope, anginal or non-anginal chest pains, and palpitations.

Clinical exam findings include sustained LV impulse, sytolic murmur, S4 sound, bifid carotid carotid upstroke and spike and dome arterial pulse.

Systolic murmur due to LVOT obstruction and or mitral regurgitation, usually at the left sternal border.

Transthoracic echocardiogram findings in hypertrophic cardiomyopathy include asymmetric LVH, an LV wall thickness of a 15 mm or greater in patients without another cardiac or systemic causes and left ventricular outflow tract obstruction on Doppler ultrasound.

Asymmetric LVH is most commonly associated with hypertrophic cardiomyopathy, however symmetrical LVH does not exclude the diagnosis.

Surgical mortality ranges from <2% to 5% for myectomy.

Nonsurgical myocardial reduction with dessicated alcohol infused into the first major septal perforator of the left anterior descending coronary artery associated with a hospital mortality between 0 and 4%.

In elderly patients diagnosed in the fifth or sixth decades of life have a morphological subtype of disease characterized as a sigmoid ventricular septum compared with patients diagnosed at a young age.

Older populations of patients have fewer symptoms and fewer sudden deaths.

Apical hypertrophic cardiomyopathy, also known as Yamaguchi syndrome, is a variant of hypertrophic cardiomyopathy and is relatively common in Japan.

Apical hypertrophic cardiomyopathy is rare in non-Japanese populations.

Apical hypertrophic cardiomyopathy predominately involves the apex of the left ventricle without the typical septal predominance seen hypertrophic obstructive cardiomyopathy.

Apical hypertrophic cardiomyopathy, in the absence of left ventricular outflow tract obstruction, most patients do not have a heart murmur.

Apical hypertrophic cardiomyopathy prognosis is relatively benign with a follow up with 13 1/2 years, all cause mortality 10.5% and cardiovascular mortality 1.9% (Eriksson MJ et al).

There is a pure apical form and a distal dominant form of apical hypertrophic cardiomyopathy.

With the distal dominant form of apical hypertrophic cardiomyopathy patients are more symptomatic and more likely to experience cardiovascular events.

Apical hypertrophic cardiomyopathy may be associated atrial fibrillation, myocardial infarction, apical aneurysm, ventricular arrhythmias, and sudden cardiac death.

Majority of patients with apical hypertrophic myopathy have maintained functional status, and approximately half are asymptomatic on follow up.

With modern day treatment HCM results in greater than 90%-95% of patients experiencing no mild symptoms on long-term follow up; suggesting cure.
About 5-10% of patients have unmet needs and include patients with nonobstructive hypertrophic cardiomyopathy and refractory heart failure, patients with refractory paroxysmal atrial fibrillation, nonresponders to septal myomectomy.
About 50% of patients evaluated in tertiary centers experience a silent and benign clinical course long-term without requiring significant therapeutic interventions.
Treatment strategies: primary prevention of a rhythmic sudden death with prophylactically implanted defibrillators, reversal of heart failure by relief of left ventricular outflow obstruction with low risk, high benefit surgical septal myectomy and end stage progression and heart transplant in a small number of patients who were nonobstructive with refractory heart failure, and control of atrial fibrillation, preventing embolic stroke with anticoagulation.
A large expectation for permanent improvement is associated with the above treatments, as rarely do patients experience disease progression and heart failure following implanted cardioverter-defibrillator therapy or the recurrence of outflow obstruction after operation.
Mavacamten a cardiac myosin inhibitor improves exercise capacity and reduces symptoms in patients with obstructive HCM.
Aficamten is an oral selective cardiac myosin inhibitor that reduces left ventricular outflow tract gradients by mitigating cardiac hypercontractility and significantly improves peak oxygen uptake in patients with symptomatic obstructive HCM (Maron MS).

Leave a Reply

Your email address will not be published. Required fields are marked *